MarketCapExport financials
MediciNova (MNOV)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
MediciNova Balance Sheet 2025-2000 | MNOV
Brief overview of MediciNova's financial position
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets fell from $87.4 million to $45.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Liability growth of +7.7% exceeded asset growth of -47.8%, increasing reliance on outside funding.
Equity funds 91.2% of assets versus 95.7% initially. This creates a conservative balance sheet structure.
Negative net debt of -$30.6 million means cash holdings are larger than debt obligations.
Cash represents 67.6% of assets versus 81.7% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$438.7 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Taken together, the figures indicate acceptable resilience for MediciNova. The next assessment depends on debt and equity trends.
Annual Balance Sheet MediciNova
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-30.6 M | -40 M | -50.4 M | -17.8 M | -70.6 M | -60 M | -63.8 M | -62.3 M | -28 M | -24.1 M | -22.1 M | -11.7 M | -6.7 M | -4.01 M | -15.1 M | -13.8 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
17.1 K | 211 K | 411 K | 524 K | 695 K | - | - | - | - | - | - | - | - | - | - | 9.48 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
194 K | 194 K | 216 K | 158 K | 132 K | 185 K | 217 K | - | - | - | - | - | - | - | - | 4.95 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.9 M | 2.08 M | 1.92 M | 1.9 M | 3.65 M | 3.66 M | 3.67 M | 3.66 M | 3.65 M | 3.59 M | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
3.8 M | 2.96 M | 3.28 M | 3.19 M | 2.83 M | 2.19 M | 2.23 M | 2.19 M | 2.88 M | 1.63 M | 1.49 M | 1.59 M | 460 K | 1.04 M | 3.7 M | 36.8 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.02 M | 3.37 M | 3.89 M | 3.91 M | 3.73 M | 4.09 M | 4.31 M | 4.12 M | 4.78 M | 5.28 M | 5.15 M | 5.26 M | 4.12 M | 4.69 M | 7.29 M | 48.2 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
800 K | - | - | - | - | 1.69 M | - | - | - | - | - | - | - | 3.16 K | 864 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-439 M | -427 M | -416 M | -407 M | -393 M | -383 M | -369 M | -356 M | -341 M | -330 M | -319 M | -311 M | -301 M | -296 M | -285 M | -268 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
45.6 M | 55.9 M | 66.3 M | 74.2 M | 87.4 M | 75.4 M | 79.2 M | 77.2 M | 43.4 M | 39.8 M | 37.9 M | 27.3 M | 29.5 M | 19.6 M | 30.8 M | 72.9 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
30.8 M | 40.4 M | 51 M | 18.5 M | 71.4 M | 60 M | 63.8 M | 62.3 M | 28 M | 24.1 M | 22.1 M | 11.7 M | 6.7 M | 4.01 M | 15.1 M | 28.3 M | 19.2 M | 19.3 M | - | - | - | - | - | - | - | - |
Book Value |
41.6 M | 52.5 M | 62.4 M | 70.2 M | 83.7 M | 71.3 M | 74.9 M | 73.1 M | 38.6 M | 34.5 M | 32.8 M | 22 M | 25.4 M | 14.9 M | 23.5 M | 24.7 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
41.6 M | 52.5 M | 62.4 M | 70.2 M | 83.7 M | 71.3 M | 74.9 M | 73.1 M | 38.6 M | 34.5 M | 32.8 M | 22 M | 25.4 M | 14.9 M | 23.5 M | 24.7 M | 40 M | 48 M | 66.6 M | 101 M | 136 M | 7.67 M | 4.57 M | 1.12 M | 8.05 M | 4.85 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet MediciNova
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
17.1 K | - | 211 K | 74.4 K | 117 K | 165 K | 211 K | 255 K | 302 K | 351 K | 411 K | 464 K | 520 K | 489 K | 524 K | 556 K | 587 K | 633 K | 695 K | 738 K | - | 2.21 K | 2.7 K | - | - | - | 183 K | 239 K | 279 K | 236 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.02 M | 3.3 M | 3.37 M | 3.61 M | 2.97 M | 2.5 M | 3.37 M | 3.05 M | 3 M | 3.06 M | 3.89 M | 3.47 M | 3.54 M | 3.41 M | 3.91 M | 5.29 M | 4.63 M | 3.81 M | 3.73 M | 5.14 M | 4.45 M | 3.73 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 4.31 M | 4.31 M | 4.31 M | 4.31 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 4.78 M | 4.78 M | 4.78 M | 4.78 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 5.15 M | 5.15 M | 5.15 M | 5.15 M | 5.26 M | 5.26 M | 5.26 M | 5.26 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 4.69 M | 4.69 M | 4.69 M | 4.69 M | 7.29 M | 7.29 M | 7.29 M | 7.29 M |
Deferred Revenue |
370 K | 800 K | 370 K | 800 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.16 K | 3.16 K | 3.16 K | 3.16 K | 864 K | 864 K | 864 K | 864 K |
Retained Earnings |
-439 M | -441 M | -427 M | -436 M | -433 M | -430 M | -427 M | -424 M | -421 M | -418 M | -416 M | -414 M | -413 M | -410 M | -407 M | -404 M | -400 M | -396 M | -393 M | -391 M | -387 M | -383 M | -383 M | -383 M | -383 M | -383 M | -369 M | -369 M | -369 M | -369 M | -356 M | -356 M | -356 M | -356 M | -341 M | -341 M | -341 M | -341 M | -330 M | -330 M | -330 M | -330 M | -319 M | -319 M | -319 M | -319 M | -311 M | -311 M | -311 M | -311 M | -301 M | -301 M | -301 M | -301 M | -297 M | -296 M | -296 M | -296 M | -285 M | -285 M | -285 M | -285 M |
Total Assets |
45.6 M | 42.7 M | 55.9 M | 47.6 M | 49.8 M | 52.4 M | 55.9 M | 58.1 M | 60.4 M | 62.9 M | 66.3 M | 68.1 M | 68.7 M | 71.1 M | 74.2 M | 78.4 M | 81.2 M | 84.2 M | 87.4 M | 91.6 M | 93.7 M | 96.1 M | 75.4 M | 75.4 M | 75.4 M | 75.4 M | 79.2 M | 79.2 M | 79.2 M | 79.2 M | 77.2 M | 77.2 M | 77.2 M | 77.2 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 37.9 M | 37.9 M | 37.9 M | 37.9 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M |
Cash and Cash Equivalents |
30.8 M | 27.3 M | 40.4 M | 32.6 M | 34.3 M | 36.6 M | 40.4 M | 42.3 M | 44.3 M | 47.1 M | 51 M | 51.5 M | 52.9 M | 55.3 M | 18.5 M | 52.5 M | 65.2 M | 67.7 M | 71.4 M | 75 M | 77.8 M | 76.3 M | 60 M | 60 M | 60 M | 60 M | 63.8 M | 63.8 M | 63.8 M | 63.8 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 28 M | 28 M | 28 M | 28 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 4.01 M | 4.01 M | 4.01 M | 4.01 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M |
Book Value |
41.6 M | 39.4 M | 52.5 M | 44 M | 46.9 M | 49.9 M | 52.5 M | 55.1 M | 57.4 M | 59.8 M | 62.4 M | 64.7 M | 65.2 M | 67.7 M | 70.2 M | 73.1 M | 76.6 M | 80.4 M | 83.7 M | 86.5 M | 89.2 M | 92.4 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 73.1 M | 73.1 M | 73.1 M | 73.1 M | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 22 M | 22 M | 22 M | 22 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M |
Total Shareholders Equity |
52.5 M | 39.4 M | 62.4 M | 44 M | 46.9 M | 49.9 M | 52.5 M | 55.1 M | 57.4 M | 59.8 M | 62.4 M | 64.7 M | 65.2 M | 67.7 M | 70.2 M | 73.1 M | 76.6 M | 80.4 M | 83.7 M | 86.5 M | 89.2 M | 92.4 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | 73.1 M | 73.1 M | 73.1 M | 73.1 M | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 22 M | 22 M | 22 M | 22 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of MediciNova, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Niderland
Israel
Russia
China
France
Germany
Britain
Belgium
Canada